We also expect that net income for the full year will be in the range of $20,000,000 to $24,000,000 We anticipate that for Q3 2023, NANELIX product revenue, net, We'll be in the range of $51,000,000 to $53,000,000 Also, we expect Q3 royalty revenue will be in the range of $3,000,000 to $5,000,000 Further estimate that the gross to net adjustment in Q3 2023 will be approximately 17.5 percent 18.5%. We anticipate a Q3 net profit between $3,000,000 $4,000,000 SG and A expenses were $24,400,000 in the Q2 of 2023 compared to $22,500,000 for the Q1. SG and A expenses included noncash charges for stock based compensation of $1,800,000 for Q2 2023 Compared to $2,000,000 for Q1 2023, research and development expenses were $13,400,000 in the Q2 of 2023 Compared to $12,700,000 for the Q1, R and D expenses included noncash charges for stock based compensation of $800,000 in the Q2 of 2023 compared to $900,000 in the Q1. In the Q2 of 2023, Puma reported cash earned of approximately $3,200,000 This compares to cash burn of approximately $9,900,000 in Q1 2023, which included $12,500,000 payment to Pfizer related to The achievement of our global revenue milestone and an $8,000,000 payment related to Aligozarma.